hsa-miR-132-3p miREIA

Features

• It is intended for research use only
• The total assay time is less than 2.5 hours
• The kit measures hsa-miR-132-3p isolated from human blood
• Assay format is 96 wells
• Standard is synthetic miRNA-based
• Components of the kit are provided ready to use, concentrated or dried

Research topic

Cardiovascular disease, Oncology, Neurodegenerative disease

Summary

MicroRNAs (miRNAs) are small non-coding RNA molecules, approximately 22 nucleotides in length that regulate gene translation through silencing or degradation of target mRNAs. They are involved in multiple biological processes, including differentiation and proliferation, metabolism, hemostasis, apoptosis or inflammation, and in pathophysiology of many diseases. Numerous studies have suggested circulating miRNAs as promising diagnostic and prognostic biomarkers of many diseases.

miR-132-3p is downregulated in many types of carcinomas. miR-132-3p suppressed the migration and invasion of breast carcinoma cells. Down regulation of miR-132-3p has also been found in colorectal cancer (CRC). Overexpression of long non-coding RNA and CAMP Responsive Element Binding Protein 5 resulted in the enhancement of proliferation, metastasis, migration and the inhibition of apoptosis in CRC cells, while miR-132-3p led to the opposite result. miR-132-3p was found to be down-regulated during the osteogenic differentiation of ligamentum flavum cells and negatively regulated osteoblast differentiation. In addition, miR-132-3p was dramatically down-regulated in CD19+ lymphocytes isolated from peripheral blood mononuclear cells (PBMCs) of mantle cell lymphoma patients.

hsa-miR-132-3p is considered one of the angiogenic miRNAs. The circulating miR-132-3p showed different expression levels between mesothelioma patients and asbestos-exposed controls. Overexpressing miR-132-3p or knocking down taurine upregulated gene 1 significantly alleviated ischemia-reperfusion induced AMI (acute myocardial infarction) in vivo.

Increase of miR-132-3p expression in white blood cells of neuropathy patients has been compared to healthy controls. miR-132-3p expression was also slightly up-regulated in sural nerve biopsies from neuropathy patients suffering from neuropathic pain compared to those without pain. Levels of miR-132-3p in neurally-derived plasma extracellular vesicles showed good sensitivity and specificity to diagnose Alzheimer's disease (AD), but did not effectively separate individuals with AD and mild cognitive impairment (MCI) from controls. It was observed that miR-132-3p and miR-146a-5p expressions were significantly decreased in the serum samples of patients with Parkinson’s disease (PD) compared to those in the healthy volunteers. Moreover, the expressions of miR-132-3p and miR-146a-5p showed a dramatic decrease in severe PD patients as compared to patients with less severe PD. Both miRNAs appear be useful as promising biomarkers for early diagnosis of PD.